The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers

In this study, we assess whether SYNB1353, an E. coli Nissle 1917 derivative, impacts circulating methionine and homocysteine levels in animals and healthy volunteers. In both mice and nonhuman primates (NHPs), SYNB1353 blunts the appearance of plasma methionine and plasma homocysteine in response to an oral methionine load. A phase 1 clinical study conducted in healthy volunteers subjected to an oral methionine challenge demonstrates that SYNB1353 is well tolerated and blunts plasma methionine by 26%. Overall, SYNB1353 represents a promising approach for methionine reduction with potential utility for the treatment of HCU.PMID:38309259 | DOI:10.1016/j.chom.2024.01.005

Source: Cell Host and Microbe - February 3, 2024 Category: Microbiology Authors: Myl ène Perreault Jillian Means Erik Gerson Michael James Sean Cotton Christopher G Bergeron Mark Simon Dylan Alexander Carlin Nathan Schmidt Theodore C Moore Julie Blasbalg Neal Sondheimer Kenneth Ndugga-Kabuye William S Denney Vincent M Isabella David Source Type: research